BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29062135)

  • 1. Increased HSP27 correlates with malignant biological behavior of non-small cell lung cancer and predicts patient's survival.
    Sheng B; Qi C; Liu B; Lin Y; Fu T; Zeng Q
    Sci Rep; 2017 Oct; 7(1):13807. PubMed ID: 29062135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer.
    Wang D; Hao T; Pan Y; Qian X; Zhou D
    Mol Cell Biochem; 2015 Apr; 402(1-2):75-82. PubMed ID: 25567207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and significance of hypoxia inducible factor-1α and lysyl oxidase in non-small cell lung cancer.
    Ping W; Jiang WY; Chen WS; Sun W; Fu XN
    Asian Pac J Cancer Prev; 2013; 14(6):3613-8. PubMed ID: 23886154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer.
    Zhang T; Yu TT; Zhang DM; Hou XM; Liu XJ; Zhao D; Shan L
    Med Oncol; 2014 May; 31(5):963. PubMed ID: 24748406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High TBX2 expression predicts poor prognosis in non-small cell lung cancer.
    Zhang Z; Guo Y
    Neoplasma; 2014; 61(4):476-80. PubMed ID: 25027744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients.
    Wei LX; Zhou RS; Xu HF; Wang JY; Yuan MH
    Tumour Biol; 2013 Apr; 34(2):941-6. PubMed ID: 23264086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer.
    Han KY; Gu X; Wang HR; Liu D; Lv FZ; Li JN
    Tumour Biol; 2013 Apr; 34(2):821-5. PubMed ID: 23229099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of 14-3-3γ overexpression in advanced non-small cell lung cancer.
    Raungrut P; Wongkotsila A; Lirdprapamongkol K; Svasti J; Geater SL; Phukaoloun M; Suwiwat S; Thongsuksai P
    Asian Pac J Cancer Prev; 2014; 15(8):3513-8. PubMed ID: 24870749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study.
    Li H; Zhou RJ; Zhang GQ; Xu JP
    Tumour Biol; 2013 Jun; 34(3):1807-12. PubMed ID: 23471668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HSPA2 is expressed in human tumors and correlates with clinical features in non-small cell lung carcinoma patients.
    Scieglinska D; Gogler-Piglowska A; Butkiewicz D; Chekan M; Malusecka E; Harasim J; Habryka A; Krawczyk Z
    Anticancer Res; 2014 Jun; 34(6):2833-40. PubMed ID: 24922646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p114RhoGEF predicts lymph node metastasis and poor survival of squamous-cell lung carcinoma patients.
    Song C; Gao Y; Tian Y; Han X; Chen Y; Tian DL
    Tumour Biol; 2013 Jun; 34(3):1925-33. PubMed ID: 23512329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+, IL17 and Foxp3 expression in different pTNM stages of operable non-small cell lung cancer and effects on disease prognosis.
    Zhang GQ; Han F; Fang XZ; Ma XM
    Asian Pac J Cancer Prev; 2012; 13(8):3955-60. PubMed ID: 23098499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional promoter -1271G>C variant of HSPB1 predicts lung cancer risk and survival.
    Guo H; Bai Y; Xu P; Hu Z; Liu L; Wang F; Jin G; Wang F; Deng Q; Tu Y; Feng M; Lu D; Shen H; Wu T
    J Clin Oncol; 2010 Apr; 28(11):1928-35. PubMed ID: 20231684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer.
    Liu CL; Chen SF; Wu MZ; Jao SW; Lin YS; Yang CY; Lee TY; Wen LW; Lan GL; Nieh S
    Oncotarget; 2016 Mar; 7(12):14279-90. PubMed ID: 26872057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome.
    Wang X; Du Z; Li L; Shi M; Yu Y
    Int J Clin Exp Pathol; 2015; 8(9):10644-52. PubMed ID: 26617774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GOLPH3 high expression predicts poor prognosis in patients with resected non-small cell lung cancer: an immunohistochemical analysis.
    Zhang Y; Ma M; Han B
    Tumour Biol; 2014 Nov; 35(11):10833-9. PubMed ID: 25081375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The overexpression of 14-3-3ζ and Hsp27 promotes non–small cell lung cancer progression.
    Zhao GY; Ding JY; Lu CL; Lin ZW; Guo J
    Cancer; 2014 Mar; 120(5):652-63. PubMed ID: 24804299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.
    Ni SS; Zhang J; Zhao WL; Dong XC; Wang JL
    Tumour Biol; 2013 Jun; 34(3):1813-8. PubMed ID: 23475633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.